Forte Biosciences (FBRX) Misses Q2 EPS by 4c

Forte Biosciences (NASDAQ: FBRX) reported Q2 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Forte Biosciences (FBRX) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts